Current and future treatment strategies for rhabdomyosarcoma

C Chen, H Dorado Garcia, M Scheer… - Frontiers in …, 2019 - frontiersin.org
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be
subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last …

Parthanatos and its associated components: promising therapeutic targets for cancer

Y Zhou, L Liu, S Tao, Y Yao, Y Wang, Q Wei… - Pharmacological …, 2021 - Elsevier
Parthanatos is a PARP1-dependent, caspase-independent, cell-death pathway that is
distinct from apoptosis, necrosis, or other known forms of cell death. Parthanatos is a …

[HTML][HTML] Mechanism of PARP inhibitor resistance and potential overcoming strategies

X Fu, P Li, Q Zhou, R He, G Wang, S Zhu, A Bagheri… - Genes & diseases, 2024 - Elsevier
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose)
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …

PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation

AR Michmerhuizen, AM Pesch, L Moubadder… - Molecular cancer …, 2019 - AACR
Sustained locoregional control of disease is a significant issue in patients with inflammatory
breast cancer (IBC), with local control rates of 80% or less at 5 years. Given the …

PARP inhibitors combined with radiotherapy: are we ready?

C Sun, A Chu, R Song, S Liu, T Chai… - Frontiers in …, 2023 - frontiersin.org
PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in
repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in …

Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment

S Genta, F Martorana, A Stathis, I Colombo - Critical Reviews in Oncology …, 2021 - Elsevier
Cancer derives from alterations of pathways responsible for cell survival, differentiation and
proliferation. Dysfunctions of mechanisms protecting genome integrity can promote …

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines

S Camero, S Ceccarelli, F De Felice… - Journal of cancer …, 2019 - Springer
Purpose PARP inhibitors (PARPi) are used in a wide range of human solid tumours but a
limited evidence is reported in rhabdomyosarcoma (RMS), the most frequent childhood soft …

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials

J Luo, X Dai, H Hu, J Chen, L Zhao, C Yang… - Journal of cancer …, 2020 - Springer
Propose Poly (ADP-ribose) polymerase 1 inhibitors were originally investigated as anti-
cancer therapeutics with BRCA1/2 genes mutation. Here, we investigate the effectiveness of …

Unraveling the Myth of Radiation Resistance in Soft Tissue Sarcomas

LM Wiltink, AB Miah, AN Scholten, RL Haas - Seminars in Radiation …, 2024 - Elsevier
There is a misconception that sarcomas are resistant to radiotherapy. This manuscript
summarizes available (pre-) clinical data on the radiosensitivity of soft tissue sarcomas …

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers

J Przybycinski, M Nalewajska… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: The implementation of poly-ADP-ribose polymerase (PARP) inhibitors for
therapy has created potential treatments for a wide spectrum of malignancies involving DNA …